These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9281254)

  • 1. [Adjuvant CMF chemotherapy in patients with breast cancer--results on blood coagulation and fibrinolysis].
    Oberhoff C; Winkler UH; Tauchert AM; Schindler AE
    Zentralbl Gynakol; 1997; 119(5):211-7. PubMed ID: 9281254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prothrombotic state in breast cancer patients treated with adjuvant chemotherapy.
    Rella C; Coviello M; Giotta F; Maiello E; Colavito P; Colangelo D; Quaranta M; Colucci G; Schittulli F
    Breast Cancer Res Treat; 1996; 40(2):151-9. PubMed ID: 8879681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant CMF-chemotherapy and haemostasis. Effect of "classical" and "modified" adjuvant CMF-chemotherapy on blood coagulation fibrinolysis in patients with breast cancer.
    Oberhoff C; Winkler UH; Hoffmann O; Schindler AE
    Eur J Gynaecol Oncol; 2000; 21(2):147-52. PubMed ID: 10843473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T; Sano M; Takashima S; Kitaya T; Tokuda Y; Yoshimoto M; Kohno N; Nakagami K; Iwata H; Shimozuma K; Sonoo H; Tsuda H; Sakamoto G; Ohashi Y
    J Clin Oncol; 2009 Mar; 27(9):1368-74. PubMed ID: 19204202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The potential risk of neoadjuvant chemotherapy in breast cancer patients--results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07).
    Taucher S; Steger GG; Jakesz R; Tausch C; Wette V; Schippinger W; Kwasny W; Reiner G; Greil R; Dubsky P; Poestlberger S; Tschmelitsch J; Samonigg H; Gnant M;
    Breast Cancer Res Treat; 2008 Nov; 112(2):309-16. PubMed ID: 18080748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M; Tu D; Shepherd L; Levine M; Bramwell V; Pritchard K
    J Clin Oncol; 2003 Aug; 21(16):3066-71. PubMed ID: 12915595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
    Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrophysiological correlates of information processing in breast-cancer patients treated with adjuvant chemotherapy.
    Kreukels BP; Schagen SB; Ridderinkhof KR; Boogerd W; Hamburger HL; van Dam FS
    Breast Cancer Res Treat; 2005 Nov; 94(1):53-61. PubMed ID: 16175317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Results of a study on fatigue in breast cancer patients receiving adjuvant chemotherapy: the first four days after treatment are the worst].
    de Jong N; Kester AD; Schouten HC; Abu-Saad HH; Courtens AM
    Pflege Z; 2007 Nov; 60(11):620-5. PubMed ID: 18062627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of adjuvant chemotherapy in breast carcinoma with a combination of cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and AC (doxorubicin, cyclophosphamide). Initial results of a national cooperative study].
    Pribylová O; Petruzelka L; Honová H; Fischer J; Bustová I; Siffnerová H; Kůta M; Miller V; Hacklová M; Machácek J; Kohoutek M; Vodvárka P; Kyselá T; Tajblová J; Suk J; Dorazilová V; Bauer J
    Sb Lek; 1998; 99(1):25-31. PubMed ID: 9748796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF.
    Poikonen P; Saarto T; Lundin J; Joensuu H; Blomqvist C
    Br J Cancer; 1999 Aug; 80(11):1763-6. PubMed ID: 10468293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant chemotherapy with anthracyclines in comparison with the standard combination of CMF in breast cancer with high risk of relapse].
    Semiglazov VF; Bozhok AA; Ivanova OA; Ivanov VG; Arzumanov AS; Barash NIu; Orlov AA; Golubëva OM; Topuzov EE; Seleznev IK; Migmanova NSh; Popova PT; Brezhneva TV; Paltuev RM
    Vopr Onkol; 2000; 46(2):160-6. PubMed ID: 10853413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma.
    Mayers C; Panzarella T; Tannock IF
    Cancer; 2001 Jun; 91(12):2246-57. PubMed ID: 11413512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evolution of adjuvant chemotherapy of breast cancer from Bonadonna to the taxanes].
    Nagykálnai T
    Magy Onkol; 2002; 46(4):307-13. PubMed ID: 12563352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of a dose-intensive CMF regimen with granulocyte colony-stimulating factor as adjuvant therapy in premenopausal patients with node-positive breast cancer.
    Bos AM; de Graaf H; de Vries EG; Piersma H; Willemse PH
    Br J Cancer; 2000 Jun; 82(12):1920-4. PubMed ID: 10864198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.